Azide-Modified MscL Channel Proteins for Controlled Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems, particularly liposomes, lack universal control over drug release, which is influenced by various factors such as redox state, pH, and light, limiting their applicability and effectiveness in targeting specific tissues and achieving controlled release.
Innovation Solution
Modification of mechanosensitive channel proteins like MscL with phosphine-reactive azide groups allows for controlled drug release through the Staudinger reaction, enabling tailored therapeutic protocols by administering phosphine to activate the channel proteins within lipid vesicles, thereby regulating the release of bioactive agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liposomes are used for drug delivery, then drug encapsulation and targeted delivery are improved, but control over drug release timing and location is insufficient
Solution Approach 1:
The patent modifies the MscL channel protein by incorporating non-natural amino acids with specific chemical properties (azide groups, fluorophores, biotin tags) at precise locations. This allows the channel's gating behavior to be controlled by changing chemical parameters (pH, redox state, ligand binding) rather than relying on mechanical forces alone, enabling precise control over drug release timing and location
Solution Approach 2:
The patent introduces small molecule mediators that bind to the modified MscL channel protein to trigger conformational changes and gate opening. These intermediators act as chemical keys that convert external signals (pH changes, redox state, light) into channel opening events, providing indirect but precise control over drug release
2Reliability
If MscL channel proteins are modified with non-natural amino acids, then controlled drug release is improved, but protein synthesis complexity increases
Solution Approach 1:
The patent divides the complex task of producing modified MscL channels into separate manageable steps: (1) synthesizing the non-natural amino acid building blocks with desired functional groups, (2) incorporating them into the MscL sequence using established methods (genetic code expansion or chemical synthesis), and (3) reconstituting the purified protein into liposomes. This segmentation makes the overall process more controllable and scalable
Solution Approach 2:
The patent performs preliminary synthesis and characterization of the non-natural amino acids and their incorporation into MscL before the actual drug delivery experiments. This preliminary action ensures that the modified proteins are fully characterized and functional before being used in complex in vivo or in vitro studies, reducing trial-and-error and improving reproducibility
3Ease of operation
If channel proteins are used in vesicles, then drug release control is improved, but vesicle manufacturing complexity increases
Solution Approach 1:
The patent merges the MscL channel protein incorporation step with the liposome formation process by using detergent-mediated reconstitution. The purified MscL (with or without non-natural amino acids) is mixed with lipid detergent solutions, and upon detergent removal, the channels are co-assembled with the lipids into functional liposomes. This merging eliminates separate incorporation steps and simplifies manufacturing
4Ease of operation
If azide groups are introduced into MscL, then Staudinger reaction control is improved, but protein stability may be compromised
Solution Approach 1:
The patent introduces azide groups at specific local positions on the MscL channel (such as at the gating helix or substrate binding site) rather than throughout the entire protein. This localized modification allows the Staudinger reaction to occur at functionally critical sites while leaving the rest of the protein structure intact and stable, maintaining overall protein stability while enabling controlled drug release
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides superior control over drug release profiles, increasing the therapeutic window and efficacy of drugs by allowing targeted and controlled delivery of therapeutic molecules, even in tissues with similar pH levels to non-target tissues.
Implementation Method 1
Modification of mechanosensitive channel proteins like MscL with phosphine-reactive azide groups allows for controlled drug release through the Staudinger reaction
Data Source
Figure 1
Figure 2~3-I
Figure 3-II
AI summary
The present invention describes the modification of polypeptides, more particularly channel proteins with a thiol reactive agent so as to introduce an azide group. The present invention further describes vesicles comprising channel proteins modified according to the invention, which upon reaction with a phosphine open up thereby releasing the content of the vesicles. The reagents, polypeptides and vesicles described in the present invention have in vivo and in vitro applications in both drug delivery and imaging.